Abstract 79: Trastuzumab and C6.5 diabody armed with deBouganin overcome drug resistance to ADCs comprised of anti-microtubule agents
Abstract DeBouganin (deB) is a de-immunized form of bouganin, a Ribosome Inactivating Protein (RIP) that when internalized blocks protein synthesis thereby leading to cell death. When conjugated to trastuzumab (T-deB) or genetically attached to the C6.5 diabody, deBouganin was more potent than DM1 a...
Saved in:
Published in | Cancer research (Chicago, Ill.) Vol. 77; no. 13_Supplement; p. 79 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
01.07.2017
|
Online Access | Get full text |
Cover
Loading…
Abstract | Abstract
DeBouganin (deB) is a de-immunized form of bouganin, a Ribosome Inactivating Protein (RIP) that when internalized blocks protein synthesis thereby leading to cell death. When conjugated to trastuzumab (T-deB) or genetically attached to the C6.5 diabody, deBouganin was more potent than DM1 and unaffected by mechanisms of resistance to which DM1 is susceptible. To further highlight the differentiating mechanism of action of deBouganin, HCC1419 and BT-474 tumor cells that survived T-DM1 or trastuzumab-MMAE (T-MMAE) treatment in vitro were re-exposed to T-DM1, T-MMAE, or treated with T-deB or an anti-HER2 C6.5 diabody-deBouganin fusion protein. C6.5 diabody-deBouganin and T-deB were potent against HCC1419 and BT-474 cells surviving T-DM1 or T-MMAE treatment. However, the surviving cell populations were resistant to T-DM1, T-MMAE, DM1, MMAE and taxol treatment. In addition, cross-resistance was seen against trastuzumab-duocarmycin which contains a payload with a cell cycle independent mechanism of action. The contribution of multi-drug resistance, Bcl-2 family members and other survival pathways accounting for the resistant phenotype will be discussed. Overall, the data suggest that treatment with chemotherapeutics or ADCs comprised of small molecule compounds such as anti-microtubule agents, can lead to the outgrowth of tumor cells resistant to similar agents. In contrast, antibodies and antibody fragments armed with deBouganin can overcome these mechanisms of resistance and may therefore represent a more effective treatment option.
Citation Format: Shilpa Chooniedass, Rachelle L. Dillon, Arjune Premsukh, Gregory P. Adams, Glen C. MacDonald, Jeannick Cizeau. Trastuzumab and C6.5 diabody armed with deBouganin overcome drug resistance to ADCs comprised of anti-microtubule agents [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 79. doi:10.1158/1538-7445.AM2017-79 |
---|---|
AbstractList | Abstract
DeBouganin (deB) is a de-immunized form of bouganin, a Ribosome Inactivating Protein (RIP) that when internalized blocks protein synthesis thereby leading to cell death. When conjugated to trastuzumab (T-deB) or genetically attached to the C6.5 diabody, deBouganin was more potent than DM1 and unaffected by mechanisms of resistance to which DM1 is susceptible. To further highlight the differentiating mechanism of action of deBouganin, HCC1419 and BT-474 tumor cells that survived T-DM1 or trastuzumab-MMAE (T-MMAE) treatment in vitro were re-exposed to T-DM1, T-MMAE, or treated with T-deB or an anti-HER2 C6.5 diabody-deBouganin fusion protein. C6.5 diabody-deBouganin and T-deB were potent against HCC1419 and BT-474 cells surviving T-DM1 or T-MMAE treatment. However, the surviving cell populations were resistant to T-DM1, T-MMAE, DM1, MMAE and taxol treatment. In addition, cross-resistance was seen against trastuzumab-duocarmycin which contains a payload with a cell cycle independent mechanism of action. The contribution of multi-drug resistance, Bcl-2 family members and other survival pathways accounting for the resistant phenotype will be discussed. Overall, the data suggest that treatment with chemotherapeutics or ADCs comprised of small molecule compounds such as anti-microtubule agents, can lead to the outgrowth of tumor cells resistant to similar agents. In contrast, antibodies and antibody fragments armed with deBouganin can overcome these mechanisms of resistance and may therefore represent a more effective treatment option.
Citation Format: Shilpa Chooniedass, Rachelle L. Dillon, Arjune Premsukh, Gregory P. Adams, Glen C. MacDonald, Jeannick Cizeau. Trastuzumab and C6.5 diabody armed with deBouganin overcome drug resistance to ADCs comprised of anti-microtubule agents [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 79. doi:10.1158/1538-7445.AM2017-79 |
Author | Cizeau, Jeannick Chooniedass, Shilpa Adams, Gregory P. Premsukh, Arjune MacDonald, Glen C. Dillon, Rachelle L. |
Author_xml | – sequence: 1 givenname: Shilpa surname: Chooniedass fullname: Chooniedass, Shilpa – sequence: 2 givenname: Rachelle L. surname: Dillon fullname: Dillon, Rachelle L. – sequence: 3 givenname: Arjune surname: Premsukh fullname: Premsukh, Arjune – sequence: 4 givenname: Gregory P. surname: Adams fullname: Adams, Gregory P. – sequence: 5 givenname: Glen C. surname: MacDonald fullname: MacDonald, Glen C. – sequence: 6 givenname: Jeannick surname: Cizeau fullname: Cizeau, Jeannick |
BookMark | eNo9kM1OwzAQhC0EEm3hCbjsC6TYcVzH3EL4lYq49B5t_FOCmhjZDqjceW9SFXFazY5mdvXNyengB0vIFaNLxkR5zQQvM1kUYlm95JTJTKoTMvvfnpIZpbTMRCHzczKP8X2SglExIz9VG1NAnUCqG9gEjGn8HntsAQcD9WopwHTYerMHDL018NWlNzD21o9bHLoB_KcN2vcWTBi3EGzsYsJBW0geqrs6wmR-hC5OUe-m0tRlfaeDT2M77izg1g4pXpAzh7toL__mgmwe7jf1U7Z-fXyuq3WmVaEyw7nThWKlVWjQFkyXgjuKwnGeO1VSZ2jBKLdslTMpqZGqdUKWOWrkQuR8QfixdrofY7CumT7rMewbRpsDyOaArDkga44gG6n4L0uYaS8 |
CitedBy_id | crossref_primary_10_3390_toxins15120699 |
ContentType | Journal Article |
DBID | AAYXX CITATION |
DOI | 10.1158/1538-7445.AM2017-79 |
DatabaseName | CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | CrossRef |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1538-7445 |
EndPage | 79 |
ExternalDocumentID | 10_1158_1538_7445_AM2017_79 |
GroupedDBID | --- -ET 18M 29B 2WC 34G 39C 476 53G 5GY 5RE 5VS 6J9 AAYXX ABOCM ACGFO ACIWK ACPRK ACSVP ADBBV ADCOW ADNWM AENEX AFHIN AFOSN AFRAH ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW CITATION CS3 DIK DU5 EBS EJD F5P FRP GX1 H13 IH2 KQ8 L7B LSO OK1 P0W P2P PQQKQ RCR RHF RHI RNS SJN TR2 W2D W8F WH7 WOQ YKV YZZ |
ID | FETCH-LOGICAL-c949-d33fc4918e9adae41c853f0a5f332f980fd04103e1621770d79bf5782aca35523 |
ISSN | 0008-5472 |
IngestDate | Thu Sep 26 18:10:01 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 13_Supplement |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c949-d33fc4918e9adae41c853f0a5f332f980fd04103e1621770d79bf5782aca35523 |
PageCount | 1 |
ParticipantIDs | crossref_primary_10_1158_1538_7445_AM2017_79 |
PublicationCentury | 2000 |
PublicationDate | 2017-07-01 |
PublicationDateYYYYMMDD | 2017-07-01 |
PublicationDate_xml | – month: 07 year: 2017 text: 2017-07-01 day: 01 |
PublicationDecade | 2010 |
PublicationTitle | Cancer research (Chicago, Ill.) |
PublicationYear | 2017 |
SSID | ssj0005105 |
Score | 2.2788916 |
Snippet | Abstract
DeBouganin (deB) is a de-immunized form of bouganin, a Ribosome Inactivating Protein (RIP) that when internalized blocks protein synthesis thereby... |
SourceID | crossref |
SourceType | Aggregation Database |
StartPage | 79 |
Title | Abstract 79: Trastuzumab and C6.5 diabody armed with deBouganin overcome drug resistance to ADCs comprised of anti-microtubule agents |
Volume | 77 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JjtNAEG2FQUJcEKvY1QduxsZr7OZmMqAREMQSpLlZ3e7yJJBl5NgH5s6f8iFUL140jBDDxUqsuNNJPdfmV1WEPAMWhhjKRq4vpO-i9pMuy_B-FCBKkGiBS93UZ_5hevQ1fnucHE8mv0aspbYRXnl2YV3J_0gVz6FcVZXsJSTbL4on8DXKF48oYTz-k4xzoRIVZeOkTKfJa75v2rN2w4V-JjCbeolOru7kD4fXm45pLuEVus1ctVVVBE7cGTiybk8cDL2VO6nudXRJ88PZXlPOUQ_gpYowsG1W7kZR-JpWtGtw-EnXCmrU7aCE2rE9hJb6IbFhe2httF57o9zDbLlDlQKSm8ntX5ar9WlvJg5XHSXgMzd0Vee912vyGjb79rvOCeX1t3YgB-TSZo9s9Y3z0RtnNoK0Z8EO2jpzk9iM9vFgUNBpbFpQdhrcDoKxSI0KPRB1YA4Z1Wxm1lgjb978aT4SVRLRf4eXz_W-ukvHzbrPGdGe2qiDqiQr1CKFWqQwixQpu0KuhilLFPH03aehp31iibbdr7W9sXCRFxfsZOQ_jRyhxU1yw0YwNDdwvEUmsL1Nrs0tR-MO-dmhkqbsJR1hkiImqcIktZikGpNUYZIOmKQdJqnCJB0wSZsdVZikPSbprqLnMUkNJu-SxZvXi9mRa4d9uCWLmSujqCpjFmTAuOQQByX6kZXPkyqKwoplfiX9OPAjCKYYRKe-TJmo1CgGXnJ0mcPoHjnY7rZwn1AmfQhkKJIApnEQSAFhlQKTZaiqxqv4AXne_YPFqWnpUvxFag8v9_FH5PqA5cfkoKlbeIJ-ayOearH_BlkAlNw |
link.rule.ids | 315,786,790,27955,27956 |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Abstract+79%3A+Trastuzumab+and+C6.5+diabody+armed+with+deBouganin+overcome+drug+resistance+to+ADCs+comprised+of+anti-microtubule+agents&rft.jtitle=Cancer+research+%28Chicago%2C+Ill.%29&rft.au=Chooniedass%2C+Shilpa&rft.au=Dillon%2C+Rachelle+L.&rft.au=Premsukh%2C+Arjune&rft.au=Adams%2C+Gregory+P.&rft.date=2017-07-01&rft.issn=0008-5472&rft.eissn=1538-7445&rft.volume=77&rft.issue=13_Supplement&rft.spage=79&rft.epage=79&rft_id=info:doi/10.1158%2F1538-7445.AM2017-79&rft.externalDBID=n%2Fa&rft.externalDocID=10_1158_1538_7445_AM2017_79 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0008-5472&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0008-5472&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0008-5472&client=summon |